Abbott Biotechnology Ltd.

Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abbott Laboratories Corporation

Dow Global Technolgoies LLC

Dow Agrosciences LLC

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbvie Biotechnology Ltd

Michael White

Boris Labkovsky

Jochen G Salfeld

Zehra Kaymakcalan

Paul Sakorafas

John A Mankovich

Tristan J Vaughan

Brian Timothy McGuinness

David Schoenhaut

Deborah J Allen

Andrew J Roberts

Alison Jane Wilton

Hendricus R J M Hoogenboom

Michael Roguska

Alexander Robert Duncan

Geertruida Machteld Veldman

Nicholas W Warne

Subhashis Banerjee

Angela Widom

Thor Las Holtet

Daniel Edward Tracey

Elaine Joy Derbyshire

John Gawain Elvin

Sara Carmen

Michael Paskind

Sarah Leila Du Fou

Stuart Friedrich

Amy Venturini

Stephen Smith

Angela Myles

Joan D Tyner

Phillip J Howard

David J Hawksworth

Robert N Ziemann

Bailin Tu

James W Scheffel

John A Naumovitz

Robin A Gutierrez

Kumar Nanjundiah

Mary S Pinkus

Angela Kantor

John D Busacca

Anthony Weiss

Charles A Carn

Jeffrey M Werneke

Ian Van Wesenbeeck

Brian T Mcguinness

Richard W Dixon

Hendricus Renerus Hoogenboom

Dennis Lane

John Dennis Lane

Hendricus Rjm Hoogenboom

Tariq Ghayer

Simon Mark Brocklehurst

Celia Patricia Shorrock

Julia Elizabeth Thompson

Simon Nicholas Lennard

Alison J Wilton

Hendricus RJM Hoogenboom

Brian T Mcguiness

Hendricus R Hoogenboom

Boris Labkovksy

An electronic device comprises a first encapsulating film in direct contact with a light-receiving and transmitting film and a second encapsulating film in direct contact with a back sheet. The first encapsulating film has a zero shear viscosity greater than that of the second encapsulating film. The back sheet of the electronic device contains fewer bumps than the back sheet of a comparable electronic device having a first encapsulating film with a zero shear viscosity less than or equal to that of the second encapsulating film.

Electronic devices comprising two encapsulant films

Methods for fumigating soil include applying over fumigant-treated soil a multilayer polymeric film to form a vapor barrier between the fumigant-treated soil and the atmosphere to at least partially contain the fumigant. The multilayer film includes at least one barrier layer comprising at least one vinylidene chloride polymer and protecting layers on each side of the barrier layer. The multilayer film preferably has at least one UV protecting layer and optionally at least one reflective layer.

Agricultural fumigation using a multilayer film including a PVDC vapor barrier

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Methods for fumigating soil include providing a fumigant including at least one volatile substance into or onto soil and applying over the soil a multilayer polymeric film to form a vapor barrier between the fumigant-treated soil and the atmosphere to at least partially contain the fumigant. The multilayer film includes at least one barrier layer comprising at least one vinylidene chloride polymer and protecting layers on each side of the barrier layer. The multilayer film preferably has at least one UV protecting layer and optionally at least one reflective layer.

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1;

Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.

Recombinant antibodies against hepatitis C virus and methods of obtaining and using same

Human antibodies that bind human TNF&#x3b1; and methods of using same

Methods of treating disorders using human antibodies that bind human TNF&#x3b1;

Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

Growing community of inventors

Framingham, MA, United States of America

Michael White